AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00635882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate/formoterol 100/10 mcg
Description: mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
Study NCT00635882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate/formoterol 200/10 mcg
Description: mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
Study NCT00635882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate/formoterol 400/10 mcg
Description: mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
Study NCT00635882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF DPI 200 mcg
Description: MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
Study NCT00635882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF MDI 200 mcg
Description: MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
Study NCT00635882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MF/F MDI placebo twice daily (BID) (2 inhalations)
Study NCT06293768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous wireless monitoring system of Vital Signs (Win@Hospital) + continuous system for continuous monitoring of blood sugar (Dexcom G6)(only for diabetic patients)
Description: Patients randomized to the experimental group on discharge or with transfer to the subacute ward will be connected to the system continuous monitoring of Vital Signs(Win@Hospital) continuous system for the continuous monitoring of blood sugar(Dexcom G6)(only for diabetic patients). The system, once applied, does not require the presence of a dedicated person and continuous monitoring in real time. It is set with alerts that are triggered both when the parameters they leave the normal ranges both if the data is not recorded due to technical problems. the data is transmitted in real time on mobile devices in the possession of a doctor and a nurse available 24 hours a day who guarantee the remote control system. Devices. Mobiles also contain the clinical information of each patient.
Study NCT01380834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
Study NCT00957736 — intervention group
Intervention type: GENETIC
Intervention: polymorphism analysis
Description: Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
Study NCT00957736 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
Study NCT02038257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using dermabrasion.
Study NCT03093259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: ABX464 is a new Anti-inflammatory drug
Study NCT03093259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo matching with ABX464
Study NCT01380834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment group
Description: Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
Study NCT04659525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Study NCT01304056 — intervention group
Intervention type: DEVICE
Intervention: Ventilatory therapy
Study NCT01395927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
Study NCT01395927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
Study NCT03267212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation(NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Study NCT03267212 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Non-invasive ventilation(NIV)
Description: The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
Study NCT03267212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training
Study NCT03267212 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Functional Electrical Stimulation Row Training (FESRT)
Description: FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training
Study NCT01893515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-4016
Study NCT03328741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Osteoarthritis treatment
Description: 6 week online-program
Study NCT01893515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02934243 — intervention group
Intervention type: DEVICE
Intervention: laryngeal mask insertion
Description: airway management with laryngeal mask
Study NCT03437408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mapping and ablation
Description: High density substrate map. Data collection during ablation
Study NCT01311687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 4 mg pomalidomide capsules administered orally
Study NCT01311687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg dexamethasone (or 20 mg for participants > 75 years of age) tablets administered orally
Study NCT01311687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg dexamethasone (or 20 mg for participants > 75 years of age) tablets administered orally
Study NCT03328741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face osteoarthritis treatment
Description: 3 months face-to-face program
Study NCT02605720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
Study NCT04926129 — intervention group
Intervention type: OTHER
Intervention: Other: Assessments
Description: Administered as specified in the treatment arm.
Study NCT03249532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard hemodialysis
Description: hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
Study NCT02107781 — intervention group
Intervention type: DEVICE
Intervention: AbViser abdominal compartment pressure measuring device
Description: AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
Study NCT03249532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cool hemodialysis
Description: hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
Study NCT03249532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low volume hemodiafiltration
Description: hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
Study NCT03249532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high volume hemodiafiltration
Description: hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
Study NCT00919295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
Study NCT00919295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04076163 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: serious game
Description: a serious game was performed by the investigators in order to enhance the critical appraisal practice of students
Study NCT02263287 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LeSCoD scale
Description: LeSCoD is a clinical scale
Study NCT03889886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDP-4 Ophthalmic Solution (0.1%)
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Study NCT03889886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDP-4 Ophthalmic Solution (1.0%)
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Study NCT03889886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDP-4 Ophthalmic Solution (3.0%)
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Study NCT03889886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Study NCT02556957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthScouts
Study NCT02556957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Study NCT02556957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study NCT02421055 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Roux-en-Y Gastric Bypass
Study NCT02421055 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Sleeve Gastrectomy
Study NCT04662814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shock wave therapy
Description: Intervention group is by shock wave therapy. A radial shock wave device (EME, ITALY) was used. for 4 sessions (one session before the expected day of period and session per day for day1 , day 2 and day 3 of each menstrual cycle) for three successive periods.
Study NCT04662814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary modification
Description: Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months
Study NCT04662814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary modification
Description: Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months
Study NCT04659525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
Study NCT04659525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
Study NCT04659525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Study NCT01185795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt
Description: yogurt, twice per day (BID), 6 weeks
Study NCT03222843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: once daily
Study NCT04318015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: All treatment will be administered orally.
Study NCT04318015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: All placebo will be administered orally
Study NCT03222843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: once daily
Study NCT01902446 — intervention group
Intervention type: DRUG
Intervention: Chlorhexidine gluconate
Description: Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
Study NCT00902564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Flexible-dosed (5 to 20 mg Oral Tablets Daily)
Study NCT00588445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.~Patients who have had at least a minor response to gefitinib therapy preoperatively (> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.~Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy.
Study NCT04255004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pall Celeris System, point of care device for human cell therapy
Description: Concentration of PB-MNCs autologous cell therapy was produced by a filtration-based point-of-care device. All the procedures were performed in operatory room with anaesthesiologic support (propofol and/or peripheral block). Blood withdrawal (120 ml) was collected through a peripheral venous access. Blood was loaded, and gravity filtration was allowed to proceed until the upstream side of the filter had no remaining blood; filtration last about 10 minutes. During filtration, MNCs were captured in the filter while plasma, platelets (PLTs) and red blood cells (RBCs) were not retained. Immediately concentrate solution is injected in the perilesional area and intramuscular in the foot and the leg (0.2-0.3cc in boluses) below the knee, at intervals of 1-2 cm and to a mean depth of 1.5-2 cm, using a 21G needle. This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
Study NCT02788708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate
Description: Given PO
Study NCT00579059 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Maxim® Knee System with Removable Molded Polyethylene Tibia
Description: Used for total knee replacements
Study NCT00579059 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Regular Maxim® Knee System
Description: Used for total knee replacements
Study NCT03092076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180 mg loading dose
Study NCT02452320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous acetaminophen
Description: administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
Study NCT02452320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
Study NCT00310440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-15 Synthetic osteoconductive bone substitute
Description: Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
Study NCT00310440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone
Description: Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
Study NCT02185638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Appetite suppressant properties of YGD and A20-50
Description: 3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
Study NCT02185638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Appetite suppressant properties of YGD and A20-50
Description: 3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
Study NCT02185638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Appetite suppressant properties of YGD and A20-50
Description: 3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
Study NCT01251666 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Colonoscopy
Description: Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
Study NCT03898882 — intervention group
Intervention type: DRUG
Intervention: oxytocin
Description: PK measurements of oxytocin
Study NCT03898882 — intervention group
Intervention type: DEVICE
Intervention: Shore durometer
Description: The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
Study NCT02643420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-2012
Description: Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
Study NCT02643420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Single-dose subcutaneous injection administered on Day 2 of each cycle
Study NCT02643420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Standard therapy
Study NCT02643420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard therapy
Study NCT01928186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Undergo FLT PET
Study NCT04551950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
Study NCT04551950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered intravenously as per standard of care.